ESTA vs. BLCO, INSP, SLNO, PRCT, NVST, LIVN, WRBY, NVCR, LMAT, and ENOV
Should you be buying Establishment Labs stock or one of its competitors? The main competitors of Establishment Labs include Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), PROCEPT BioRobotics (PRCT), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), and Enovis (ENOV). These companies are all part of the "medical equipment" industry.
Establishment Labs vs. Its Competitors
Establishment Labs (NASDAQ:ESTA) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.
Bausch + Lomb has a net margin of -6.62% compared to Establishment Labs' net margin of -46.13%. Bausch + Lomb's return on equity of 3.35% beat Establishment Labs' return on equity.
Establishment Labs received 80 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 62.05% of users gave Establishment Labs an outperform vote while only 40.59% of users gave Bausch + Lomb an outperform vote.
In the previous week, Bausch + Lomb had 4 more articles in the media than Establishment Labs. MarketBeat recorded 10 mentions for Bausch + Lomb and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.86 beat Bausch + Lomb's score of 0.14 indicating that Establishment Labs is being referred to more favorably in the media.
72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 11.1% of Establishment Labs shares are owned by insiders. Comparatively, 0.8% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Establishment Labs has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.
Establishment Labs has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
Establishment Labs presently has a consensus price target of $52.40, indicating a potential upside of 41.16%. Bausch + Lomb has a consensus price target of $15.54, indicating a potential upside of 24.93%. Given Establishment Labs' stronger consensus rating and higher possible upside, research analysts clearly believe Establishment Labs is more favorable than Bausch + Lomb.
Summary
Establishment Labs beats Bausch + Lomb on 10 of the 17 factors compared between the two stocks.
Get Establishment Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Establishment Labs Competitors List
Related Companies and Tools
This page (NASDAQ:ESTA) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ESTA Stock Free ESTA Stock Alerts